Corbus Pharma Reports Director/Officer Changes & Compensation
Ticker: CRBP · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1595097
Sentiment: neutral
Topics: management-change, governance, filing
Related Tickers: CRBP
TL;DR
Corbus Pharma (CRBP) filed an 8-K detailing director/officer changes and compensation. Watch for updates.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on August 20, 2024, reporting events as of August 15, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
Changes in key personnel and compensation arrangements can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and director positions can indicate internal shifts that may affect company direction and stability.
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
- August 20, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Norwood, Massachusetts (location) — Principal Executive Offices
FAQ
What specific director or officer departures are detailed in the filing?
The filing indicates the 'Departure of Directors or Certain Officers' as an item of information, but the specific names and details of these departures are not provided in the excerpt.
Who were the newly elected directors or appointed officers?
The filing lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items, but the specific individuals are not named in the provided text.
Are there any details on new compensatory arrangements?
Yes, the filing mentions 'Compensatory Arrangements of Certain Officers' as a reported item, suggesting new or updated compensation plans are being disclosed.
What is the significance of the Regulation FD Disclosure mentioned?
A Regulation FD Disclosure indicates that the company is providing material non-public information to the public in compliance with fair disclosure rules, often related to events or announcements.
When was Corbus Pharmaceuticals Holdings, Inc. incorporated?
Corbus Pharmaceuticals Holdings, Inc. was incorporated in Delaware, as stated in the filing.
Filing Stats: 1,353 words · 5 min read · ~5 pages · Grade level 11.4 · Accepted 2024-08-20 08:15:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
- $40,000 — e Board, an annual cash retainer fee of $40,000 for board members and $20,000 for servi
- $20,000 — er fee of $40,000 for board members and $20,000 for serving as chair of the Audit Commi
Filing Documents
- crbp-20240815.htm (8-K) — 53KB
- crbp-ex99_1.htm (EX-99.1) — 19KB
- 0000950170-24-098861.txt ( ) — 198KB
- crbp-20240815.xsd (EX-101.SCH) — 31KB
- crbp-20240815_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 20, 2024, the Company issued a press release announcing the appointment of Mr. Kung to its Board of Directors. A copy of the press release is furnished as Exhibit 99.1 hereto and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated August 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: August 20, 2024 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer